IRF5 and systemic lupus erythematosus: Ex vivo human studies demonstrated that an IRF5 inhibitor blocked SLE serum-induced IRF5 activation in healthy immune cells and significantly reduced basal IRF5 hyper-activation in SLE immune cells (181).